Speciality Medicines Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹0(0.00%)
Premium (ELP)
Having completed its public offering, Speciality Medicines Limited's is now listed and trading on the BSE exchange as of Mar 30, 2026. The IPO raised cumulative capital of 23,50,000 Shares, including 23,50,000 Shares in primary capital infusion.
The IPO was conducted with a price range of ₹117 to ₹124 and minimum investment requirement of 1000 shares. subscription activity between Mar 20, 2026 and Mar 24, 2026 reflected market assessment of the offering's valuation and prospects.
The allotment process finalized on Mar 25, 2026 distributed equity ownership to successful bidders. The listing established a transparent market mechanism for share trading, price discovery, and investor participation in the company's future growth.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Speciality Medicines Limited was incorporated in 2021 and focuses on marketing and distributing speciality pharmaceutical medicines, including expensive oral and injectable drugs used to treat serious and long-term health conditions in both Indian and international markets. The company offers many types of finished pharmaceutical products in different forms such as tablets, capsules, creams, syrups, eye drops, gels, injections, inhalers, nasal sprays, ointments, sachets, and suspensions. It operates through two main models: contract manufacturing of finished medicines for international markets and marketing and distribution of speciality medicines sourced from other manufacturers. The company has expanded globally with products registered or under registration in countries like Jordan, Ethiopia, Uganda, Peru, and Namibia, and its distribution network covers more than 20 states in India and over 35 countries worldwide. As of March 31, 2025, one product was registered overseas and 60 products were under registration in five countries, contributing to revenue, and as of August 31, 2025, the company had 18 permanent employees working in different departments.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Wide Global Presence: The company operates in India as well as several international markets, helping it build a diversified revenue base and reduce dependence on a single region.
- Strong Customer Relationships: By focusing on customer needs, timely delivery, and consistent product quality, the company has developed long-term relationships and receives repeat orders from its clients.
- Reliable Quality Standards: The company follows strict quality control practices supported by ISO 9001:2015 certification and trusted third-party manufacturing facilities, ensuring consistent product quality and on-time delivery.
- Dependence on Third-Party Suppliers: The company relies on external suppliers for sourcing products. Any disruption, delay, or price fluctuations from these suppliers may affect product availability, pricing, and overall operations.
- Strict Quality Compliance Requirements: The company’s products must meet specific customer specifications and quality standards. Any failure to meet these requirements may result in product recalls, order cancellations, or warranty claims.
- Limited In-House R&D Capability: The company currently does not have a well-established in-house R&D team. Delays in developing this capability may impact product innovation and future growth opportunities.
- Parth B Goyani
- Goyani Sumit Babubhai
Speciality Medicines Limited
Skyline Financial Services Private Limited